Supplementary Figure S5 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Wenyi Sun,Zuoquan Xie,Yifu Liu,Dan Zhao,Zhixiang Wu,Dadong Zhang,Hao Lv,Shuai Tang,Nan Jin,Hualiang Jiang,Minjia Tan,Jian Ding,Cheng Luo,Jian Li,Min Huang,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22410417

2023-01-01

Abstract:The variable growth dependency of different cell lines on PDK1.

What problem does this paper attempt to address?

Supplementary Figure S4 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Wenyi Sun,Zuoquan Xie,Yifu Liu,Dan Zhao,Zhixiang Wu,Dadong Zhang,Hao Lv,Shuai Tang,Nan Jin,Hualiang Jiang,Minjia Tan,Jian Ding,Cheng Luo,Jian Li,Min Huang,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22410420

2023-01-01

Abstract:The variable abundance of PDK1 in different cell lines.
Supplementary Figure S7 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Wenyi Sun,Zuoquan Xie,Yifu Liu,Dan Zhao,Zhixiang Wu,Dadong Zhang,Hao Lv,Shuai Tang,Nan Jin,Hualiang Jiang,Minjia Tan,Jian Ding,Cheng Luo,Jian Li,Min Huang,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22410411.v1

2023-01-01

Abstract:Cysteine 240 is critical for the enzymatic activity of PDK1 in A549 cells.
Supplementary Figure S3 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Wenyi Sun,Zuoquan Xie,Yifu Liu,Dan Zhao,Zhixiang Wu,Dadong Zhang,Hao Lv,Shuai Tang,Nan Jin,Hualiang Jiang,Minjia Tan,Jian Ding,Cheng Luo,Jian Li,Min Huang,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22410423

2023-01-01

Abstract:PDK inhibition by JX06 in different cancer cells.
Supplementary Figure S2 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Wenyi Sun,Zuoquan Xie,Yifu Liu,Dan Zhao,Zhixiang Wu,Dadong Zhang,Hao Lv,Shuai Tang,Nan Jin,Hualiang Jiang,Minjia Tan,Jian Ding,Cheng Luo,Jian Li,Min Huang,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22410426

2023-01-01

Abstract:JX06 exhibits no inhibitory effect on FAK at the cellular level.
Supplementary Figure S8 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Wenyi Sun,Zuoquan Xie,Yifu Liu,Dan Zhao,Zhixiang Wu,Dadong Zhang,Hao Lv,Shuai Tang,Nan Jin,Hualiang Jiang,Minjia Tan,Jian Ding,Cheng Luo,Jian Li,Min Huang,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22410408.v1

2023-01-01

Abstract:Comparison of MMP level in four indicated cell lines after JX06 treatment.
Supplementary Figure S6 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Wenyi Sun,Zuoquan Xie,Yifu Liu,Dan Zhao,Zhixiang Wu,Dadong Zhang,Hao Lv,Shuai Tang,Nan Jin,Hualiang Jiang,Minjia Tan,Jian Ding,Cheng Luo,Jian Li,Min Huang,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22410414

2023-01-01

Abstract:Chemical structure of biotin-conjugated JX06 and activity in PDK1 inhibition.
Supplementary Table S3 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Wenyi Sun,Zuoquan Xie,Yifu Liu,Dan Zhao,Zhixiang Wu,Dadong Zhang,Hao Lv,Shuai Tang,Nan Jin,Hualiang Jiang,Minjia Tan,Jian Ding,Cheng Luo,Jian Li,Min Huang,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22410432

2023-01-01

Abstract:JX06 activity at 10 μM towards a panel of 323 kinases.
Supplementary Information from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Wenyi Sun,Zuoquan Xie,Yifu Liu,Dan Zhao,Zhixiang Wu,Dadong Zhang,Hao Lv,Shuai Tang,Nan Jin,Hualiang Jiang,Minjia Tan,Jian Ding,Cheng Luo,Jian Li,Min Huang,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22410405

2023-01-01

Abstract:Supplementary experimental procedures and figure legend
Supplementary Table S2 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Wenyi Sun,Zuoquan Xie,Yifu Liu,Dan Zhao,Zhixiang Wu,Dadong Zhang,Hao Lv,Shuai Tang,Nan Jin,Hualiang Jiang,Minjia Tan,Jian Ding,Cheng Luo,Jian Li,Min Huang,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22410435.v1

2023-01-01

Abstract:Activity of JX06 and DCA against PDK1-4.
Supplementary Table S1 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Wenyi Sun,Zuoquan Xie,Yifu Liu,Dan Zhao,Zhixiang Wu,Dadong Zhang,Hao Lv,Shuai Tang,Nan Jin,Hualiang Jiang,Minjia Tan,Jian Ding,Cheng Luo,Jian Li,Min Huang,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22410438

2023-01-01

Abstract:An enzymatic screen towards PDK1 using a small molecule library composed of 591 commercially available known drugs.
Supplementary Figure S1 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Wenyi Sun,Zuoquan Xie,Yifu Liu,Dan Zhao,Zhixiang Wu,Dadong Zhang,Hao Lv,Shuai Tang,Nan Jin,Hualiang Jiang,Minjia Tan,Jian Ding,Cheng Luo,Jian Li,Min Huang,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22410429

2023-01-01

Abstract:Thiram inhibits PDK activity in A549 cells.
Supplementary Movie S1 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Wenyi Sun,Zuoquan Xie,Yifu Liu,Dan Zhao,Zhixiang Wu,Dadong Zhang,Hao Lv,Shuai Tang,Nan Jin,Hualiang Jiang,Minjia Tan,Jian Ding,Cheng Luo,Jian Li,Min Huang,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22410441

2023-01-01

Abstract:A 200 ns molecular dynamic simulation of the open conformation PDK1, in which the sidechain of R286 swung towards different sides.
Supplementary Figure from Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy

Mario R. Fernandez,Franz X. Schaub,Chunying Yang,Weimin Li,Seongseok Yun,Stephanie K. Schaub,Frank C. Dorsey,Min Liu,Meredith A. Steeves,Andrea Ballabio,Alexandar Tzankov,Zhihua Chen,John M. Koomen,Anders E. Berglund,John L. Cleveland

DOI: https://doi.org/10.1158/0008-5472.22431502

2023-01-01

Abstract:Supplementary Figure from Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy
Supplementary Figure 1 from Determination of the Role of Target Tissue Metabolism in Lung Carcinogenesis Using Conditional Cytochrome p450 Reductase-Null Mice

Wei Yan,Cheng Fang,Robert J. Turesky,Melissa Behr,Laurence S. Kaminsky,Xinxin Ding

DOI: https://doi.org/10.1158/0008-5472.22368285.v1

2023-01-01

Abstract:Supplementary Figure 1 from Determination of the Role of Target Tissue Metabolism in Lung Carcinogenesis Using Conditional Cytochrome P450 Reductase-Null Mice
Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors

Yifu Liu,Zuoquan Xie,Dan Zhao,Jin Zhu,Fei Mao,Shuai Tang,Hui Xu,Cheng Luo,Meiyu Geng,Min Huang,Jian Li

DOI: https://doi.org/10.1021/acs.jmedchem.6b01245

IF: 8.039

2017-01-01

Journal of Medicinal Chemistry

Abstract:Pyruvate dehydrogenase kinases (PDKs) are overexpressed in most cancer cells and are responsible for aberrant glucose metabolism. We previously described bis(4-morpholinyl thiocarbonyl)-disulfide (JX06, 16) as the first covalent inhibitor of PDK1. Here, on the basis of the scaffold of 16, we identify two novel types of disulfide-based PDK1 inhibitors. The most potent analogue, 3a, effectively inhibits PDK1 both at the molecular (kinact/Ki = 4.17 × 103 M-1 s-1) and the cellular level (down to 0.1 μM). In contrast to 16, 3a is a potent and subtype-selective inhibitor of PDK1 with >40-fold selectivity for PDK2-4. 3a also significantly alters glucose metabolic pathways in A549 cells by decreasing ECAR and increasing ROS. Moreover, in the xenograft models, 3a shows significant antitumor activity with no negative effect to the mice weight. Collectively, these data demonstrate that 3a may be an excellent lead compound for the treatment of cancer as a first-generation subtype-selective and covalent PDK1 inhibitor.
Supplementary Figure S5 from Upregulation of Cytosolic Phosphoenolpyruvate Carboxykinase is a Critical Metabolic Event in Melanoma Cells That Repopulate Tumors

Yong Li,Shunqun Luo,Ruihua Ma,Jing Liu,Pingwei Xu,Huafeng Zhang,Ke Tang,Jingwei Ma,Yi Zhang,Xiaoyu Liang,Yanling Sun,Tiantian Ji,Ning Wang,Bo Huang

DOI: https://doi.org/10.1158/0008-5472.22410005.v1

2023-01-01

Abstract:Supplementary Figure S5. Inhibition of PCK1 enzymatic activity repressed TRC growth and PCK1 knockdown didn't affect B16 TRC apoptosis.
Figure S7 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Fang Wang,Xiao-Mei Qi,Ryan Wertz,Matthew Mortensen,Catherine Hagen,John Evans,Yuri Sheinin,Michael James,Pengyuan Liu,Susan Tsai,James Thomas,Alexander Mackinnon,Michael Dwinell,Charles R. Myers,Ramon Bartrons Bach,Liwu Fu,Guan Chen

DOI: https://doi.org/10.1158/0008-5472.22423419.v1

2023-01-01

Abstract:Figure S7. PFD collaborates with PFK15 to inhibit glucose uptake, lactate secretion, and Pdac growth and upregulated p-PFKFB3 in Pdac specimens is positively correlated with overexpressed p38ÃƒÅ½Ã,Â³ and Glut2.
Supplementary Table 1 from Serine Catabolism Regulates Mitochondrial Redox Control during Hypoxia

Jiangbin Ye,Jing Fan,Sriram Venneti,Ying-Wooi Wan,Bruce R. Pawel,Ji Zhang,Lydia W.S. Finley,Chao Lu,Tullia Lindsten,Justin R. Cross,Guoliang Qing,Zhandong Liu,M. Celeste Simon,Joshua D. Rabinowitz,Craig B. Thompson

DOI: https://doi.org/10.1158/2159-8290.22530234

2023-01-01

Abstract:Knockdown of SHMT2 reduces xenograft growth in vivo.
Figure S5 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Fang Wang,Xiao-Mei Qi,Ryan Wertz,Matthew Mortensen,Catherine Hagen,John Evans,Yuri Sheinin,Michael James,Pengyuan Liu,Susan Tsai,James Thomas,Alexander Mackinnon,Michael Dwinell,Charles R. Myers,Ramon Bartrons Bach,Liwu Fu,Guan Chen

DOI: https://doi.org/10.1158/0008-5472.22423425

2023-01-01

Abstract:Figure S5. PFD decreases p-PFKFB3, PFKFB3 and Glut2 expression in primary KPC tumors and suppresses allograft growth of KPC, but not KPC/p38ÃƒÅ½Ã,Â³ KO tumor, in association with decreased Ki67, p-PFKFB3, PFKFB3 and ÃƒÅ½Ã,Â±-SMA expression in tumor tissues.
Supplementary Figure S6 from Upregulation of Cytosolic Phosphoenolpyruvate Carboxykinase Is a Critical Metabolic Event in Melanoma Cells That Repopulate Tumors

Yong Li,Shunqun Luo,Ruihua Ma,Jing Liu,Pingwei Xu,Huafeng Zhang,Ke Tang,Jingwei Ma,Yi Zhang,Xiaoyu Liang,Yanling Sun,Tiantian Ji,Ning Wang,Bo Huang

DOI: https://doi.org/10.1158/0008-5472.22410002.v1

2023-01-01

Abstract:Supplementary Figure S6. TRCs lost PCK1 expression in conventional rigid dish and inhibition of PCK1 enzymatic activity resulted in the decrease of bulk tumor cell number.

Supplementary Figure S5 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Supplementary Figure S4 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Supplementary Figure S7 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Supplementary Figure S3 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Supplementary Figure S2 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Supplementary Figure S8 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Supplementary Figure S6 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Supplementary Table S3 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Supplementary Information from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Supplementary Table S2 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Supplementary Table S1 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Supplementary Figure S1 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Supplementary Movie S1 from JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification

Supplementary Figure from Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy

Supplementary Figure 1 from Determination of the Role of Target Tissue Metabolism in Lung Carcinogenesis Using Conditional Cytochrome &lt;i&gt;p&lt;/i&gt;450 Reductase-Null Mice

Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors

Supplementary Figure S5 from Upregulation of Cytosolic Phosphoenolpyruvate Carboxykinase is a Critical Metabolic Event in Melanoma Cells That Repopulate Tumors

Figure S7 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Supplementary Table 1 from Serine Catabolism Regulates Mitochondrial Redox Control during Hypoxia

Figure S5 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Supplementary Figure S6 from Upregulation of Cytosolic Phosphoenolpyruvate Carboxykinase Is a Critical Metabolic Event in Melanoma Cells That Repopulate Tumors

Supplementary Figure 1 from Determination of the Role of Target Tissue Metabolism in Lung Carcinogenesis Using Conditional Cytochrome <i>p</i>450 Reductase-Null Mice